Mark D McKee Selected Research

Poly(ADP-ribose) Polymerases (Poly ADP Ribose Polymerase)

1/2018

Addition of the PARP inhibitor veliparib plus carboplatin or carboplatin alone to standard neoadjuvant chemotherapy in triple-negative breast cancer (BrighTNess): a randomised, phase 3 trial.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Mark D McKee Research Topics

Disease

12	Neoplasms (Cancer) 01/2018 - 01/2002
4	Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung) 01/2017 - 07/2014
3	Breast Neoplasms (Breast Cancer) 01/2020 - 08/2002
3	Melanoma (Melanoma, Malignant) 01/2017 - 03/2003
2	Triple Negative Breast Neoplasms 01/2020 - 01/2018
2	Hepatocellular Carcinoma (Hepatoma) 01/2015 - 05/2006
2	Thrombocytopenia (Thrombopenia) 09/2014 - 07/2014
1	Hereditary Angioedemas 02/2024
1	Angioedema 02/2024
1	Transthyretin-Related Hereditary Amyloidosis 01/2021
1	Amyloidosis 01/2021
1	Polyneuropathies (Polyneuropathy) 01/2021
1	Ovarian Neoplasms (Ovarian Cancer) 01/2018
1	Anemia 01/2017
1	Myelodysplastic Syndromes (Myelodysplastic Syndrome) 08/2015
1	Hematologic Neoplasms (Hematological Malignancy) 08/2015
1	Colorectal Neoplasms (Colorectal Cancer) 09/2014
1	Hypothyroidism 09/2014
1	Leukopenia 07/2014
1	Neutropenia 07/2014
1	Sarcoma (Soft Tissue Sarcoma) 06/2012
1	Lung Neoplasms (Lung Cancer) 06/2012
1	Hypertension (High Blood Pressure) 06/2012
1	Thymus Neoplasms (Thymus Neoplasm) 06/2012
1	Vitiligo 01/2010
1	Lymphangioleiomyomatosis (Lymphangiomyomatosis) 12/2009
1	Persistent Infection 05/2006
1	Liver Failure 05/2006
1	Fibrosis (Cirrhosis) 05/2006
1	Renal Cell Carcinoma (Grawitz Tumor) 01/2002

Drug/Important Bio-Agent (IBA)

6	linifanibIBA 11/2015 - 06/2012
5	Carboplatin (JM8)FDA LinkGeneric 01/2018 - 07/2014
4	Paclitaxel (Taxol)FDA LinkGeneric 01/2018 - 07/2014
3	Proteins (Proteins, Gene)FDA Link 01/2021 - 09/2005
3	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA 11/2015 - 07/2014
3	Platelet-Derived Growth Factor Receptors (Platelet-Derived Growth Factor Receptor)IBA 11/2015 - 07/2014
2	Poly(ADP-ribose) Polymerase InhibitorsIBA 01/2018 - 01/2018
2	veliparibIBA 01/2018 - 01/2018
2	Phosphotransferases (Kinase)IBA 08/2015 - 07/2014
2	Monophenol Monooxygenase (Tyrosinase)IBA 12/2009 - 03/2003
2	AntigensIBA 12/2009 - 09/2005
2	T-Cell Antigen Receptors (T-Cell Receptor)IBA 09/2005 - 03/2003
2	Peptides (Polypeptides)IBA 09/2005 - 03/2003
2	Interleukin-2 (IL2)IBA 03/2003 - 01/2002
1	Kallikreins (Kallikrein)IBA 02/2024
1	CRISPR-Associated Protein 9IBA 02/2024
1	Prealbumin (Transthyretin)IBA 01/2021
1	NTLA-2001IBA 01/2021
1	Poly(ADP-ribose) Polymerases (Poly ADP Ribose Polymerase)IBA 01/2018
1	PlatinumIBA 01/2018
1	Doxorubicin (Adriamycin)FDA LinkGeneric 01/2018
1	Cyclophosphamide (Cytoxan)FDA LinkGeneric 01/2018
1	Gemcitabine FDA Link 01/2018
1	omaveloxoloneIBA 01/2017
1	Alkaline PhosphataseIBA 01/2017
1	TriterpenesIBA 01/2017
1	Biomarkers (Surrogate Marker)IBA 11/2015
1	Protein-Tyrosine Kinases (Tyrosine Kinase)IBA 11/2015
1	ilorasertibIBA 08/2015
1	Vascular Endothelial Growth Factor Receptors (VEGF Receptors)IBA 08/2015
1	Aurora KinasesIBA 08/2015
1	Azacitidine (5 Azacytidine)FDA Link 08/2015
1	Platelet-Derived Growth FactorIBA 02/2015
1	Sorafenib (BAY 43-9006)FDA Link 01/2015
1	Bevacizumab (Avastin)FDA Link 09/2014
1	Phenol (Carbolic Acid)FDA Link 01/2010
1	Ether (Diethyl Ether)IBA 01/2010
1	hydroquinone (Esoterica)FDA Link 01/2010
1	Interferon-gamma (Interferon, gamma)IBA 12/2009
1	Receptor Protein-Tyrosine Kinases (Tyrosine Kinase Receptors)IBA 04/2008
1	Antineoplastic Agents (Antineoplastics)IBA 04/2008
1	CAP1-6DIBA 04/2007
1	HLA-A Antigens (HLA-A)IBA 04/2007
1	Neoplasm Antigens (Tumor Antigens)IBA 01/2007
1	Cancer VaccinesIBA 01/2007
1	Antiviral Agents (Antivirals)IBA 05/2006
1	HLA-A2 Antigen (HLA A2 Antigen)IBA 03/2003

Therapy/Procedure

10	Therapeutics 02/2024 - 01/2002
2	Neoadjuvant Therapy 01/2020 - 01/2018
2	Immunotherapy 12/2009 - 01/2007
1	Drug Therapy (Chemotherapy) 01/2018
1	Transplantation 05/2006
1	Segmental Mastectomy (Lumpectomy) 08/2002